Clinical Trials Logo

Pyelonephritis clinical trials

View clinical trials related to Pyelonephritis.

Filter by:

NCT ID: NCT02598362 Completed - Clinical trials for Urinary Tract Infection

Pharmacokinetics of Ciprofloxacin in Pediatric Patients

Start date: April 2015
Phase: Phase 4
Study type: Interventional

Measuring serum and urine concentrations of ciprofloxacin after IV and oral administration in children aged 3 months - 17 years who are treated for urinary tract infections.

NCT ID: NCT02555059 Completed - Clinical trials for Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax

Special Drug Use Investigation of Ciproxan Injection in Pediatrics

Start date: July 15, 2016
Phase:
Study type: Observational

The objective in this study is collecting post-marketing information on the safety and efficacy of Ciproxan injection under the routine clinical practice.

NCT ID: NCT02536638 Completed - Proteinuria Clinical Trials

Proteinuria During Acute Pyelonephritis In Pregnancy

Start date: July 2015
Phase:
Study type: Observational

The purpose of this research study is to compare the amount of protein excreted by the kidneys in a 24-hour period between patients who have a kidney infection and those who do not have a kidney infection.

NCT ID: NCT02486627 Completed - Clinical trials for Acute Pyelonephritis

A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)

EPIC
Start date: January 11, 2016
Phase: Phase 3
Study type: Interventional

This was a randomized, multicenter, multinational, double-blind study comparing the efficacy and safety of plazomicin compared with meropenem followed by optional oral (PO) therapy in the treatment of cUTI, including AP, in adults.

NCT ID: NCT02420366 Completed - Bacteremia Clinical Trials

Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

Start date: May 2014
Phase:
Study type: Observational

A multi-center, retrospective study of cases of serious bacterial infections including complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP), Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Acquired Bacterial Pneumonia (VABP), and/or bacteremia caused by Carbapenem-Resistant Enterobacteriaceae (CRE)

NCT ID: NCT02321800 Completed - Clinical trials for Urinary Tract Infections

A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections

APEKS-cUTI
Start date: February 5, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study was to determine the efficacy and safety of intravenous cefiderocol (S-649266) in hospitalized adults with complicated urinary tract infections caused by Gram-negative pathogens.

NCT ID: NCT02246361 Completed - Diverticulitis Clinical Trials

Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication

EDIFIP
Start date: September 2014
Phase: Phase 4
Study type: Interventional

The purpose of this "before-after" prospective multicenter study is to assess the impact of six Patient Information Leaflets (PILs) on Doctor Patient Communication scale (DPC) and adherence scale for common acute illnesses in emergency ward.

NCT ID: NCT02168946 Completed - Bacteremia Clinical Trials

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

Start date: July 2014
Phase: Phase 3
Study type: Interventional

Vabomereā„¢, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae

NCT ID: NCT02166476 Completed - Clinical trials for Acute Pyelonephritis

Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

Start date: November 20, 2014
Phase: Phase 3
Study type: Interventional

Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).

NCT ID: NCT02080182 Completed - Pyelonephritis Clinical Trials

Effect of Acetylcysteine in Pediatric Acute Pyelonephritis.

Start date: January 2014
Phase: Phase 2
Study type: Interventional

In different studies, it has been shown that "antioxidant" utilization has favorable therapeutic effects not only on control of acute symptoms but also on prevention of delayed problems from acute and chronic pyelonephritis. According to the efficacy of acetylcysteine as a potent antioxidant, safety of this drug and side effects of similar or either less than placebo, this study was designed to evaluate the efficacy of this drug on inflammatory biomarkers of pediatric acute pyelonephritis. It is a triple-blind placebo controlled study on a population of 64 patients 1-16 years old that have "definite" or "probable" diagnosis of acute pyelonephritis in "Mofid" hospital. After randomization, patients will be given acetylcysteine or placebo with dosing according to their weight. Results of treatment are evaluated according to serum procalcitonin, C reactive protein and leukocyte count before drug prescription (baseline) and 5 days after drug prescription. Side effects are also recorded in both groups. Patients will be receiving their routine antimicrobial drugs in addition to acetylcysteine.